Free Trial

IO Biotech (IOBT) Projected to Post Earnings on Tuesday

IO Biotech logo with Medical background

Key Points

  • IO Biotech is set to announce its Q2 2025 earnings results on August 12th, with analysts predicting a loss of ($0.35) per share.
  • The company's stock recently traded at $2.11, with a trading volume of 39,725 shares, significantly less than its average volume of 217,228.
  • Wall Street analysts have issued mixed ratings on IO Biotech, with one upgrade to a "sell" rating and another maintaining a "buy" rating.
  • Need better tools to track IO Biotech? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

IO Biotech (NASDAQ:IOBT - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.

IO Biotech Stock Performance

Shares of IO Biotech stock traded down $0.08 on Friday, reaching $1.81. 358,055 shares of the company were exchanged, compared to its average volume of 597,670. IO Biotech has a 1-year low of $0.66 and a 1-year high of $2.48. The firm has a market cap of $124.51 million, a price-to-earnings ratio of -1.21 and a beta of 0.44. The company's 50-day moving average is $1.67 and its two-hundred day moving average is $1.22.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in IO Biotech stock. Jane Street Group LLC acquired a new stake in shares of IO Biotech, Inc. (NASDAQ:IOBT - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,717 shares of the company's stock, valued at approximately $26,000. 54.76% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on IOBT. HC Wainwright reiterated a "buy" rating on shares of IO Biotech in a report on Wednesday, May 14th. Wall Street Zen raised IO Biotech to a "sell" rating in a report on Saturday, June 14th.

View Our Latest Research Report on IOBT

IO Biotech Company Profile

(Get Free Report)

IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.

Recommended Stories

Earnings History for IO Biotech (NASDAQ:IOBT)

Should You Invest $1,000 in IO Biotech Right Now?

Before you consider IO Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IO Biotech wasn't on the list.

While IO Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Tesla’s Future Unleashed: Elon’s Robotics Move Changes Everything
Top Trades: Massive Gains and Costly Mistakes to Avoid
NVIDIA Earnings: All Signs Point to More Growth Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines